GRI Bio (NASDAQ:GRI) Posts Quarterly Earnings Results

by · The Cerbat Gem

GRI Bio (NASDAQ:GRI – Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($1.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.70), FiscalAI reports.

GRI Bio Price Performance

NASDAQ GRI opened at $2.26 on Thursday. GRI Bio has a fifty-two week low of $2.10 and a fifty-two week high of $80.36. The stock’s 50-day moving average is $2.43 and its two-hundred day moving average is $15.43. The firm has a market cap of $3.28 million, a P/E ratio of -0.01 and a beta of -1.22.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on GRI. Wall Street Zen lowered GRI Bio to a “strong sell” rating in a research note on Saturday, January 31st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of GRI Bio in a research note on Tuesday, April 21st. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, GRI Bio has a consensus rating of “Hold” and a consensus price target of $1,008.00.

Check Out Our Latest Stock Analysis on GRI Bio

GRI Bio Company Profile

(Get Free Report)

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.

Featured Stories